Evidence map›Paper›PMID 42908734›Full record

ArticleAmerican journal of cancer research2026

Machine learning-based quantitative pathology reveals intratumoral heterogeneity in ductal carcinoma

Libo Yang, Jie Chen, Chuanfen Lei, Miao Yang, Pengzhou Cai, Jing Fu, Ting Yin, Peilu Gao, Hongyu Wang, Zhiwei Tan and 7 more

Abstract read
In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Libo YangDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.
Jie ChenInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Chuanfen LeiDepartment of Pathology, West China Fourth Hospital, Sichuan University Chengdu, Sichuan, China.
Miao YangInstitute of Systems Science, National University of Singapore Singapore.
Pengzhou CaiInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Jing FuDepartment of Pathology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu, Sichuan, China.
Ting YinDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.
Peilu GaoDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.
Hongyu WangDepartment of Pathology, Qilu Hospital of Shandong University Qingdao, Shandong, China.
Zhiwei TanDepartment of Pathology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital Chengdu, Sichuan, China.
Chen ShuInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Li LiInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Fei ChenInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Leyi GaoDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.
Junsheng LinDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.
Yuhao YiInstitute of Clinical Pathology, NHC Key Laboratory of Transplant Engineering and Immunology, West China Hospital, Sichuan University Chengdu, Sichuan, China.
Zhang ZhangDepartment of Pathology, West China Hospital of Sichuan University Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to develop a machine learning framework for objective ductal carcinoma in situ (DCIS) grading and to investigate intratumoral heterogeneity as a predictive biomarker. The grading framework was developed using 267 DCIS resections and validated on two external test sets (n=116 and n=69). A single-cell grading model graded individual nuclei using quantitative measures of nuclear size and pleomorphism. An integrated grading model then combined single-cell with architectural features in a support vector machine classifier. Separately, an invasion prediction model was trained on 288 intermediate- and high-grade DCIS cases and validated on 54 cases to predict upstaging to invasive carcinoma >1 mm. Compared to low-grade nuclei, high-grade nuclei were significantly larger and less uniformly oriented (all P<0.001). The single-cell grading model achieved F1 scores of 0.76, 0.62, and 0.80 for low-, intermediate-, and high-grade nuclei, respectively. In one external test set, the integrated grading model achieved F1 scores of 0.83, 0.71, and 0.72 for low-, intermediate-, and high-grade DCIS, respectively. On 54 intermediate- and high-grade DCIS biopsy cases, combining clinical variables with quantitative heterogeneity metrics improved the prediction of upstaging to invasive carcinoma >1 mm over the clinical-only model, increasing the area under the receiver operating characteristic curve from 0.704 to 0.827. These findings identify quantitatively measured intratumoral heterogeneity as a biologically relevant feature that may explain diagnostic ambiguity in borderline cases and help predict extensive invasive upstaging.

Indexed as

Ductal carcinoma in situgradingintratumoral heterogeneitymachine learning

Identifiers

PMID42908734
PMCPMC13683260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.